Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07160608 | Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis | PHASE2 | RECRUITING | 75 | — | — | Nov 26, 2025 | Feb 14, 2028 | Jun 4, 2026 | 78 | Argentina, Australia +12 |
| Arm | Type | Description |
|---|---|---|
| Tarperprumig Group 1 | EXPERIMENTAL | Participants will be administered tarperprumig dose regimen #1 or dose regimen #2. |
| Tarperprumig Group 2 | EXPERIMENTAL | Participants will be administered tarperprumig dose regimen #1 or dose regimen #2. |
| Placebo Group 3 | EXPERIMENTAL | Participants will be administered placebo. |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Participants will receive placebo. |
| Tarperprumig | DRUG | Participants will receive tarperprumig. |
Inclusion Criteria: * Newly diagnosed or relapsing ANCA-associated vasculitis, GPA and MPA subtypes consistent with the 2022 ACR/EULAR classification criteria for GPA and MPA for whom treatment with rituximab or cyclophosphamide is considered. * Positive test for antibodies to either PR3-ANCA or MP...